Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia

Schizophrenia Research

Volumn 161, Issue 2-3, 2015, Pages 439-445

  Chaves, Cristiano ^a,b   Marque, Cristiane R ^a,b   Maia de Oliveira, João P ^a,b,c   Wichert Ana, Lauro ^a   Ferrari, Thiago B ^a,b   Santos, Antonio C ^a   Araújo, David ^d   Machado de Sousa, João P ^a,b   Bressan, Rodrigo A ^e   Elkis, Helio ^a   Crippa, José A ^a,b   Guimarães, Francisco S ^a   Zuardi, AntÔnio W ^a,b   Baker, Glen B ^b,f   Dursun, Serdar M ^b,f   Hallak, Jaime E C ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Science and Technology Institute for Translational Medicine (INCT TM)   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^d MCGILL UNIVERSITY   (Canada)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Minocycline; MRI; Neuroimaging; Schizophrenia; SPECT; VBM

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; MINOCYCLINE; PLACEBO; CYSTEINE; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX;

ADD ON THERAPY; ADULT; ARTICLE; BRAIN PERFUSION; BRAIN PROTECTION; BRAIN SCINTIANGIOGRAPHY; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GRAY MATTER; HUMAN; MALE; NEGATIVE SYNDROME; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; POSTERIOR CINGULATE; PRIMARY MOTOR CORTEX; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; VOXEL BASED MORPHOMETRY; ANALOGS AND DERIVATIVES; BRAIN; BRAIN CIRCULATION; DRUG COMBINATION; DRUG EFFECTS; ORGAN SIZE; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING; SIGNAL PROCESSING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CEREBROVASCULAR CIRCULATION; CYSTEINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MINOCYCLINE; ORGAN SIZE; ORGANOTECHNETIUM COMPOUNDS; PSYCHIATRIC STATUS RATING SCALES; RADIOPHARMACEUTICALS; SCHIZOPHRENIA; SIGNAL PROCESSING, COMPUTER-ASSISTED; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921612307     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.11.031     Document Type: Article

References (47)

1. Andreasen N.C., Paradiso S., O'Leary D.S. "Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?. Schizophr. Bull. 1998, 24(2):203-218.
2. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67(3):255-262.
3. Bachmann S., Bottmer C., Pantel J., Schroder J., Amann M., Essig M., Schad L.R. MRI-morphometric changes in first-episode schizophrenic patients at 14months follow-up. Schizophr. Res. 2004, 67(2-3):301-303.
4. Blackwood D.H., Glabus M.F., Dunan J., O'Carroll R.E., Muir W.J., Ebmeier K.P. Altered cerebral perfusion measured by SPECT in relatives of patients with schizophrenia. Correlations with memory and P300. Br. J. Psychiatry 1999, 175:357-366.
5. Bremner J.D., Narayan M., Staib L.H., Southwick S.M., McGlashan T., Charney D.S. Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am. J. Psychiatry 1999, 156(11):1787-1795.
6. Brett M., Johnsrude I.S., Owen A.M. The problem of functional localization in the human brain. Nat. Rev. Neurosci. 2002, 3(3):243-249.
7. Busatto G.F., Zamignani D.R., Buchpiguel C.A., Garrido G.E., Glabus M.F., Rocha E.T., Maia A.F., Rosario-Campos M.C., Campi Castro C., Furuie S.S., Gutierrez M.A., McGuire P.K., Miguel E.C. A voxel-based investigation of regional cerebral blood flow abnormalities in obsessive-compulsive disorder using single photon emission computed tomography (SPECT). Psychiatry Res. 2000, 99(1):15-27.
8. Cahn W., Hulshoff Pol H.E., Lems E.B., van Haren N.E., Schnack H.G., van der Linden J.A., Schothorst P.F., van Engeland H., Kahn R.S. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch. Gen. Psychiatry 2002, 59(11):1002-1010.
9. Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., Dursun S., Dunn G., Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26(9):1185-1193.
10. Chaves C., Marque C.R., Trzesniak C., Machado de Sousa J.P., Zuardi A.W., Crippa J.A., Dursun S.M., Hallak J.E. Glutamate-N-methyl-d-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz. J. Med. Biol. Res. 2009, 42(11):1002-1014.
11. Crippa J.A., Derenusson G.N., Ferrari T.B., Wichert-Ana L., Duran F.L., Martin-Santos R., Simoes M.V., Bhattacharyya S., Fusar-Poli P., Atakan Z., Santos Filho A., Freitas-Ferrari M.C., McGuire P.K., Zuardi A.W., Busatto G.F., Hallak J.E. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 2011, 25(1):121-130.
12. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 2008, 65(2):154-164.
13. Domercq M., Matute C. Neuroprotection by tetracyclines. Trends Pharmacol. Sci. 2004, 25(12):609-612.
14. Dougherty D.D., Shin L.M., Alpert N.M., Pitman R.K., Orr S.P., Lasko M., Macklin M.L., Fischman A.J., Rauch S.L. Anger in healthy men: a PET study using script-driven imagery. Biol. Psychiatry 1999, 46(4):466-472.
15. Friston K.J., Holmes A., Poline J.B., Price C.J., Frith C.D. Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 1996, 4(3 Pt 1):223-235.
16. Fujita Y., Ishima T., Kunitachi S., Hagiwara H., Zhang L., Iyo M., Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(2):336-339.
17. Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., Frackowiak R.S. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001, 14(1 Pt 1):21-36.
18. Good C.D., Scahill R.I., Fox N.C., Ashburner J., Friston K.J., Chan D., Crum W.R., Rossor M.N., Frackowiak R.S. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage 2002, 17(1):29-46.
19. Hoff A.L., Sakuma M., Wieneke M., Horon R., Kushner M., DeLisi L.E. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am. J. Psychiatry 1999, 156(9):1336-1341.
20. Kanahara N., Shimizu E., Sekine Y., Uchida Y., Shibuya T., Yamanaka H., Hashimoto T., Asaka T., Sasaki T., Miyatake R., Ohkami T., Fukami G., Fujisaki M., Watanabe H., Shirayama Y., Hayashi H., Hashimoto K., Asano M., Iyo M. Does hypofrontality expand to global brain area in progression of schizophrenia?: A cross-sectional study between first-episode and chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(3):410-415.
21. Kelly D.L., Vyas G., Richardson C.M., Koola M., McMahon R.P., Buchanan R.W., Wehring H.J. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr. Res. 2011, 133(1-3):257-258.
22. Kim H.S., Suh Y.H. Minocycline and neurodegenerative diseases. Behav. Brain Res. 2009, 196(2):168-179.
23. Kircher T.T., Liddle P.F., Brammer M.J., Williams S.C., Murray R.M., McGuire P.K. Neural correlates of formal thought disorder in schizophrenia: preliminary findings from a functional magnetic resonance imaging study. Arch. Gen. Psychiatry 2001, 58(8):769-774.
24. Koo M.S., Levitt J.J., Salisbury D.F., Nakamura M., Shenton M.E., McCarley R.W. A cross-sectional and longitudinal magnetic resonance imaging study of cingulate gyrus gray matter volume abnormalities in first-episode schizophrenia and first-episode affective psychosis. Arch. Gen. Psychiatry 2008, 65(7):746-760.
25. Lancaster J.L., Woldorff M.G., Parsons L.M., Liotti M., Freitas C.S., Rainey L., Kochunov P.V., Nickerson D., Mikiten S.A., Fox P.T. Automated Talairach atlas labels for functional brain mapping. Hum. Brain Mapp. 2000, 10(3):120-131.
26. Levkovitz Y., Levi U., Braw Y., Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007, 1154:154-162.
27. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., Fennig S., Treves I., Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 2010, 71(2):138-149.
28. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry 1999, 46(6):729-739.
29. Mane A., Falcon C., Mateos J.J., Fernandez-Egea E., Horga G., Lomena F., Bargallo N., Prats-Galino A., Bernardo M., Parellada E. Progressive gray matter changes in first episode schizophrenia: a 4-year longitudinal magnetic resonance study using VBM. Schizophr. Res. 2009, 114(1-3):136-143.
30. McGlashan T.H. The profiles of clinical deterioration in schizophrenia. J. Psychiatr. Res. 1998, 32(3-4):133-141.
31. Meyer-Lindenberg A. From maps to mechanisms through neuroimaging of schizophrenia. Nature 2010, 468(7321):194-202.
32. Mitelman S.A., Shihabuddin L., Brickman A.M., Hazlett E.A., Buchsbaum M.S. Volume of the cingulate and outcome in schizophrenia. Schizophr. Res. 2005, 72(2-3):91-108.
33. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(1):304-307.
34. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin. Neuropharmacol. 2008, 31(5):287-292.
35. Perez-Neri I., Ramirez-Bermudez J., Montes S., Rios C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem. Res. 2006, 31(10):1279-1294.
36. Salmond C.H., Ashburner J., Vargha-Khadem F., Connelly A., Gadian D.G., Friston K.J. Distributional assumptions in voxel-based morphometry. Neuroimage 2002, 17(2):1027-1030.
37. Smieskova R., Fusar-Poli P., Allen P., Bendfeldt K., Stieglitz R.D., Drewe J., Radue E.W., McGuire P.K., Riecher-Rossler A., Borgwardt S.J. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?-A systematic review. Curr. Pharm. Des. 2009, 15(22):2535-2549.
38. Stirling J., White C., Lewis S., Hopkins R., Tantam D., Huddy A., Montague L. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr. Res. 2003, 65(2-3):75-86.
39. Talairach J., Tournoux P. Co-planar Stereotaxic atlas of the Human Brain 1988, Thieme Medical Publishers, New York.
40. Valente A.A., Miguel E.C., Castro C.C., Amaro E., Duran F.L., Buchpiguel C.A., Chitnis X., McGuire P.K., Busatto G.F. Regional gray matter abnormalities in obsessive-compulsive disorder: a voxel-based morphometry study. Biol. Psychiatry 2005, 58(6):479-487.
41. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry 2008, 63(1):106-113.
42. 99mTc-ECD single photon emission computed tomography (SPECT) in patients with the first-episode schizophrenia. Eur. Psychiatry 2010, 25(6):361-365.
43. Walther S., Strik W. Motor symptoms and schizophrenia. Neuropsychobiology 2012, 66(2):77-92.
44. Wang L., Hosakere M., Trein J.C., Miller A., Ratnanather J.T., Barch D.M., Thompson P.A., Qiu A., Gado M.H., Miller M.I., Csernansky J.G. Abnormalities of cingulate gyrus neuroanatomy in schizophrenia. Schizophr. Res. 2007, 93(1-3):66-78.
45. Whitford T.J., Grieve S.M., Farrow T.F., Gomes L., Brennan J., Harris A.W., Gordon E., Williams L.M. Progressive grey matter atrophy over the first 2-3 years of illness in first-episode schizophrenia: a tensor-based morphometry study. Neuroimage 2006, 32(2):511-519.
46. Zhang L., Shirayama Y., Iyo M., Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32(9):2004-2010.
47. Zhou S.Y., Suzuki M., Hagino H., Takahashi T., Kawasaki Y., Matsui M., Seto H., Kurachi M. Volumetric analysis of sulci/gyri-defined in vivo frontal lobe regions in schizophrenia: precentral gyrus, cingulate gyrus, and prefrontal region. Psychiatry Res. 2005, 139(2):127-139.